If the trial succeeds, the vaccine could be the first human immunization for Lyme disease in the U.S. in two decades.
Berkeley Lovelace Jr. Pfizer has started a late-stage clinical trial to test a vaccine that aims to protect against Lyme disease, the drugmaker announced Monday. There are currently no vaccines approved in the United States for the tick-borne illness, which infects an estimated 476,000 people in the U.
S. each year, according to theIf Pfizer’s trial succeeds, the vaccine could be the first human inoculation available for Lyme disease in the U.S. in two decades. Only one other vaccine for the disease, LYMErix, has been used in the country, but it was discontinued in 2002., providing a new option for people to help protect themselves from the disease is more important than ever,” Annaliesa Anderson, Pfizer's head of vaccine research and development, said in a statement. Pfizer said it aims to enroll approximately 6,000 healthy adults and children 5 and older in the phase 3 trial, which will evaluate whether the vaccine is safe and effective. The protein-based vaccine, called VLA15, is a three-dose regimen, administered over a five-to-nine month period, followed by a booster dose 12 months later. It targets Borrelia burgdorferi, the bacteria that cause Lyme disease. The company is developing the vaccine with French biotech firm Valneva. Dr. Alan Kivitz, a rheumatologist in Pennsylvania who is a principal investigator for the trial, said that enrollment could be completed by the end of the year. Pfizer said in its news release that it could potentially submit a vaccine application for approval to the Food and Drug Administration in 2025.Lyme disease diagnoses rose 357% in rural areas and 65% in urban areas from 2007 to 2021, according to an
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer buying spree continues with $5.4B hematology dealPfizer is buying sickle cell drug maker Global Blood Therapeutics in an approximately $5.4 billion deal as it looks to accelerate growth after its revenue soared during the pandemic.
Read more »
Pfizer Agrees to $5.4 Billion Deal for Global Blood TherapeuticsPfizer has agreed to buy Global Blood Therapeutics for $5.4 billion, a deal that will give the big drugmaker a foothold in the treatment of sickle-cell disease.
Read more »
Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln dealPfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics , as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.
Read more »
Vaccine Targeting Fast-Spreading Omicron Subvariants Could Be Ready For Fall As Pfizer, BioNTech Announce TrialsPfizer and BioNTech will begin trials of their updated mRNA Covid-19 vaccine designed to protect against the newer BA.4 and BA.5 sub-variants of the coronavirus later this month.
Read more »
Pfizer to buy South SF-based Global Blood Therapeutics in $5.4B dealPfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.
Read more »
Major test of first possible Lyme vaccine in 20 years beginsResearchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years
Read more »